[Neostigmine added to bupivacaine in axillary plexus block: which benefit?].
Abstract
[INTRODUCTION] Recent study showed that neostigmine (500 microg) by intra-articular produces postoperative analgesia without adverse effect. The author's goal was to determine whether 500 microg of neostigmine added to bupivacaine in axillary plexus block could prolonged postoperative analgesia without increasing the incidence of side effects.
[METHODS] Ninety patients scheduled for orthopedic or plastic surgery with axillary plexus block were randomly assigned to one of 3 groups : group 1 (TGr n = 30) received saline solution (1 ml) in the axillary plexus, group 2 (NAGr n = 30) received 500 microg (1 ml) neostigmine in the axillary plexus and group 3.500 microg neostigmine subcutaneously (NSGr n = 30). We evaluated visual analog pain scores (VAS), the consumption of the ketoprofene, nausea and vomiting incidence during the first 24 h. ANOVA, Kruskall Wallis and Fisher tests were used for statistical analysis. A p value of <0.05 was considered significant.
[RESULTS] The VAS score was lower in NAGr (21 +/- 18) vs NSGr (31 +/- 14) and control group TGr (45 +/- 2) (p < 0.05). The consumption of the ketoprofene is 127 +/- 65 mg in NAGr vs 150 +/- 53 mg in NSGr and 200 +/- 50 mg in group TGr (p = 0.02). Incidence of nausea and vomiting was 3.5% in NAGr vs 6.8% in NSGr and 0% for TGr.
[CONCLUSION] Neostigmine combined to a mixture of lidocaine and bupivacaine prolongs postoperative analgesia after axillary plexus block.
[METHODS] Ninety patients scheduled for orthopedic or plastic surgery with axillary plexus block were randomly assigned to one of 3 groups : group 1 (TGr n = 30) received saline solution (1 ml) in the axillary plexus, group 2 (NAGr n = 30) received 500 microg (1 ml) neostigmine in the axillary plexus and group 3.500 microg neostigmine subcutaneously (NSGr n = 30). We evaluated visual analog pain scores (VAS), the consumption of the ketoprofene, nausea and vomiting incidence during the first 24 h. ANOVA, Kruskall Wallis and Fisher tests were used for statistical analysis. A p value of <0.05 was considered significant.
[RESULTS] The VAS score was lower in NAGr (21 +/- 18) vs NSGr (31 +/- 14) and control group TGr (45 +/- 2) (p < 0.05). The consumption of the ketoprofene is 127 +/- 65 mg in NAGr vs 150 +/- 53 mg in NSGr and 200 +/- 50 mg in group TGr (p = 0.02). Incidence of nausea and vomiting was 3.5% in NAGr vs 6.8% in NSGr and 0% for TGr.
[CONCLUSION] Neostigmine combined to a mixture of lidocaine and bupivacaine prolongs postoperative analgesia after axillary plexus block.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | intra-articular
|
scispacy | 1 | ||
| 해부 | TGr
|
scispacy | 1 | ||
| 해부 | NSGr
|
scispacy | 1 | ||
| 해부 | NAGr (21 +
|
scispacy | 1 | ||
| 해부 | NAGr
|
scispacy | 1 | ||
| 약물 | lidocaine
|
리도카인 | dict | 1 | |
| 약물 | Neostigmine
|
C0027679
neostigmine
|
scispacy | 1 | |
| 약물 | bupivacaine
|
C0006400
bupivacaine
|
scispacy | 1 | |
| 약물 | ketoprofene
|
C0022635
ketoprofen
|
scispacy | 1 | |
| 약물 | saline
|
scispacy | 1 | ||
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | nausea
|
C0027497
Nausea
|
scispacy | 1 | |
| 질환 | vomiting
|
C0042963
Vomiting
|
scispacy | 1 | |
| 질환 | nausea and vomiting
|
C0027498
Nausea and vomiting
|
scispacy | 1 | |
| 질환 | NAGr
|
scispacy | 1 | ||
| 기타 | axillary plexus
|
scispacy | 1 |
MeSH Terms
Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Bupivacaine; Female; Heart Rate; Humans; Ketoprofen; Lidocaine; Male; Middle Aged; Neostigmine; Nerve Block; Orthopedic Procedures; Pain Measurement; Postoperative Pain; Parasympathomimetics; Postoperative Nausea and Vomiting; Surgery, Plastic
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative effects of pharmacological interventions in the prophylactic treatment of tension-type headache: systematic review and network meta-analysis.
- Clinical safety of a low-modification hyaluronic acid filler (MoD 2%) for facial rejuvenation.
- Fat harvesting protocol for enhanced stem cell viability - pilot study.
- Medical management of refractory trigeminal neuralgia.